LightNews LightNews
banner
merusnv.bsky.social
@merusnv.bsky.social
13 followers 5 following 36 posts
Posts Replies Media Videos
merusnv.bsky.social
#NewsUpdate: Merus is now part of Genmab, a company that shares our passion for advancing antibody medicines and improving patients’ lives. Together, we enter a new chapter grounded in shared values and a goal to transforming cancer treatment.
Read the announcement here: ir.merus.nl/news-release...
December 12, 2025 at 1:00 PM
merusnv.bsky.social
We are proud to be recognized by Scrip Awards 2025 as the Biotech Company of the Year – Development-Stage.

#ClosingInOnCancer
December 11, 2025 at 11:29 PM
merusnv.bsky.social
We’re excited to highlight our grant to the #MakeSenseCampaign, part of the European Head and Neck Society, to help launch a new clinical trials resource on their website. Check it out here:

makesensecampaign.eu/en/cancer-in...

#HNSCC
#CloseInOnCancer
December 10, 2025 at 11:13 AM
merusnv.bsky.social
Warm wishes for the holidays and a bright New Year from all of us at Merus.
#CloseInOnCancer
December 9, 2025 at 11:28 AM
merusnv.bsky.social
This season, we’re thankful for our colleagues, collaborators, and the patients and families impacted by cancer, who inspire our work every day.
Happy Thanksgiving from all of us at Merus.
#CloseInOnCancer
November 26, 2025 at 11:24 AM
merusnv.bsky.social
We’re excited to share this news about our collaboration with Halozyme. Read more about here:
ir.merus.nl/news-release...

#CloseInOnCancer
November 18, 2025 at 12:15 PM
merusnv.bsky.social
Today at #Target25, we presented interim clinical data from the phase 2 trial of petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...
October 24, 2025 at 4:30 PM
merusnv.bsky.social
Interim data on petosemtamab presented today at #Targets25 demonstrate a robust response rate and a favorable, well-tolerated safety profile in metastatic colorectal cancer.

merus.nl/wp-content/u...

#CloseInOnCancer
#ColorectalCancer
October 24, 2025 at 2:02 PM
merusnv.bsky.social
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action:
-Inhibition of EGFR ligand binding and downstream signaling
-Degradation of EGFR via LGR5 internalization
-Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
October 21, 2025 at 10:53 AM
merusnv.bsky.social
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
October 15, 2025 at 10:51 AM
merusnv.bsky.social
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ir.merus.nl/news-release...
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Merus
The Investor Relations website contains information about Merus's business for stockholders, potential investors, and financial analysts.
ir.merus.nl
October 14, 2025 at 3:28 PM
merusnv.bsky.social
Merus’ plenary session oral presentation on petosemtamab in metastatic colorectal cancer will be on October 24, 10:00 -11:40 a.m. ET at #Targets25.
The poster on the preclinical evaluation of petosemtamab on cancer stem cells will be on October 24, 12:30-4:00 p.m. ET.
ir.merus.nl/news-release...
October 13, 2025 at 4:03 PM
merusnv.bsky.social
New talent. Same mission.
When we succeed, we give patients with cancer access to medicines that could change their lives.
We’re excited to welcome our new team members.
If you want to be part of something bigger, now is the time. Join us.
#CloseInOnCancer
October 13, 2025 at 11:26 AM
merusnv.bsky.social
On #WorldCancerResearchDay, we stand united with researchers around the world working towards new treatments and improved outcomes for patients living with cancer.
#CloseInOnCancer
September 24, 2025 at 4:53 AM
merusnv.bsky.social
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct MOAs:
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC

#CloseInOnCancer
September 22, 2025 at 10:15 AM
merusnv.bsky.social
Innovation drives progress – and meaningful progress comes when new therapies are both efficacious and safe. On #WorldPatientSafetyDay, and every day, we reaffirm our commitment to making patient safety a cornerstone in the development of new potential treatments for cancer.
#CloseInOnCancer
September 17, 2025 at 4:12 AM
merusnv.bsky.social
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct mechanisms of action.

Keep following as we highlight each distinct mechanism.
#CloseInOnCancer
September 16, 2025 at 5:24 AM
merusnv.bsky.social
Petosemtamab is a novel and highly innovative bispecific antibody in development for Head and Neck cancer and Colorectal cancer, with a unique mechanism of action. www.mdpi.com/2072-6694/17...

Stay tuned to learn more about petosemtamab’s unique mechanism of action.

#CloseInOnCancer #HNSCC #CRC
September 10, 2025 at 5:36 AM
merusnv.bsky.social
Our CEO Bill Lundberg will participate in a fireside chat today at the Wells Fargo Healthcare Conference. The presentation will be available on our Investors page and for a limited time thereafter.
September 4, 2025 at 10:39 AM
merusnv.bsky.social
Welcome Bharti, Matthew, and Deitmar! With multiple therapeutic candidates in the clinic, we’re building momentum toward our goal of becoming a leading oncology company. If you’re looking for a place where your work has real meaning, join us
careers.merus.nl
#CloseInOnCancer
September 3, 2025 at 10:39 AM
merusnv.bsky.social
We are proud to be developing petosemtamab, with its unique biology designed to have three distinct mechanisms of action: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system.
lnkd.in/eyGQrTpF
#CloseInOnCancer
August 26, 2025 at 10:38 AM
merusnv.bsky.social
Our CEO Bill Lundberg will participate in a fireside chat today at Canaccord Genuity’s 45th Annual Growth Conference. The presentation will be available on our Investors page and for a limited time thereafter.
August 13, 2025 at 12:39 PM
merusnv.bsky.social
During the day, we’re #ClosingInOnCancer. After hours and on weekends, we’re hitting the road. Whether mountain biking in the local forests and flower fields or raising money for worthy causes, Merus cyclists ride with passion and dedication. And yes, we even have our own Merus cycling apparel!
August 12, 2025 at 12:03 PM
merusnv.bsky.social
We’re thrilled to welcome new members to the Merus team! Their expertise and passion will help us advance our novel approach to fighting cancer.

Now is an exciting time to be part of Merus.
Interested in joining us? Explore our opportunities.

#CloseInOnCancer
August 7, 2025 at 5:31 PM
merusnv.bsky.social
When the lab coats come off and the computers shut down, the thinking caps stay on. Meet the Merus Pub Quiz crew, a highly competitive group of colleagues participating in local trivia nights. It's just one of the ways we stay connected – and sharp – when we’re off the clock.

#CloseInOnCancer
August 5, 2025 at 10:39 AM